Literature DB >> 2540731

Primary cancer of the liver. Evaluation, treatment, and prognosis.

W V McDermott1, B Cady, B Georgi, G Steele, U Khettry.   

Abstract

Between 1970 and 1985, a diagnosis of primary hepatocellular carcinoma was established in 98 patients. Sixty-one cases developed in the presence of chronic liver disease, and only six of these were considered resectable. Of these, the median survival was 19 months. There was one perioperative death. Of the 98 tumors, 37 arose in normal livers. Of the 16 patients with tumors in normal livers that were resected, all survived operation. The long-term median survival was 32 months. Two subsets of the fibrolamellar and clear-cell variants appeared to carry a more favorable prognosis.

Entities:  

Mesh:

Year:  1989        PMID: 2540731     DOI: 10.1001/archsurg.1989.01410050042007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.

Authors:  Munveer Singh Bhangoo; Diraj R Karnani; Paul N Hein; Huan Giap; Harry Knowles; Chris Issa; Steve Steuterman; Paul Pockros; Catherine Frenette
Journal:  J Gastrointest Oncol       Date:  2015-10

2.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

Review 3.  [Liver resections for primary liver malignancies. Personal results and analysis of the literature].

Authors:  J Zieren; H U Zieren; J M Müller
Journal:  Langenbecks Arch Chir       Date:  1994

4.  Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database.

Authors:  Tobias Eggert; Katherine A McGlynn; Austin Duffy; Michael P Manns; Tim F Greten; Sean F Altekruse
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.